SEC Comment Letter 0000000000-24-002417 to Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805) (NAUT)
Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805)
Date: March 4, 2024 · CIK: 0001808805 · Accession: 0000000000-24-002417
AI Filing Summary & Sentiment
File numbers found in text: 333-277437
Letter
United States securities and exchange commission logo March 4, 2024 Sujal Patel Chief Executive Officer Nautilus Biotechnology, Inc. 2701 Eastlake Avenue East Seattle, Washington 98102 Re:Nautilus Biotechnology, Inc. Registration Statement on Form S-3 Filed February 28, 2024 File No. 333-277437 Dear Sujal Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at 202-551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Zachary Myers
Show Raw Text
United States securities and exchange commission logo
March 4, 2024
Sujal Patel
Chief Executive Officer
Nautilus Biotechnology, Inc.
2701 Eastlake Avenue East
Seattle, Washington 98102
Re:Nautilus Biotechnology, Inc.
Registration Statement on Form S-3
Filed February 28, 2024
File No. 333-277437
Dear Sujal Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Ansart at 202-551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Zachary Myers